Resident's Forum
RF-2019 Classification Criteria for Systemic Lupus Erythematosus
FR-Criterios de clasificación 2019 del lupus eritematoso sistémico
L. Serra-García, P.J. Barba, D. Morgado-Carrasco
Autor para correspondencia
Departamento de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain
Leído
7122
Vecesse ha leído el artículo
2356
Total PDF
4766
Total HTML
Compartir estadísticas
array:24 [ "pii" => "S0001731022001387" "issn" => "00017310" "doi" => "10.1016/j.ad.2022.02.013" "estado" => "S300" "fechaPublicacion" => "2022-03-01" "aid" => "2927" "copyrightAnyo" => "2022" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2022;113:T310-T312" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S000173102200134X" "issn" => "00017310" "doi" => "10.1016/j.ad.2022.02.009" "estado" => "S300" "fechaPublicacion" => "2022-03-01" "aid" => "2923" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2022;113:313-5" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letter</span>" "titulo" => "Alternative Metrics as an Impact Measure for Dermatology Journals" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "313" "paginaFinal" => "315" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Métricas alternativas como medida de impacto para las publicaciones sobre dermatología" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J. Ordoñez-Parra, D.G. Fernández-Ávila, I. Cuellar-Ríos, D. Patino-Hernandez" "autores" => array:4 [ 0 => array:2 [ "nombre" => "J." "apellidos" => "Ordoñez-Parra" ] 1 => array:2 [ "nombre" => "D.G." "apellidos" => "Fernández-Ávila" ] 2 => array:2 [ "nombre" => "I." "apellidos" => "Cuellar-Ríos" ] 3 => array:2 [ "nombre" => "D." "apellidos" => "Patino-Hernandez" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173102200134X?idApp=UINPBA000044" "url" => "/00017310/0000011300000003/v2_202212210529/S000173102200134X/v2_202212210529/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S0001731021003720" "issn" => "00017310" "doi" => "10.1016/j.ad.2020.04.021" "estado" => "S300" "fechaPublicacion" => "2022-03-01" "aid" => "2785" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2022;113:310-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Foro de Residentes</span>" "titulo" => "FR-Criterios de clasificación 2019 del lupus eritematoso sistémico" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "310" "paginaFinal" => "312" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "RF-2019 Classification Criteria for Systemic Lupus Erythematosus" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "L. Serra-García, P.J. Barba, D. Morgado-Carrasco" "autores" => array:3 [ 0 => array:2 [ "nombre" => "L." "apellidos" => "Serra-García" ] 1 => array:2 [ "nombre" => "P.J." "apellidos" => "Barba" ] 2 => array:2 [ "nombre" => "D." "apellidos" => "Morgado-Carrasco" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021003720?idApp=UINPBA000044" "url" => "/00017310/0000011300000003/v2_202212210529/S0001731021003720/v2_202212210529/es/main.assets" ] "asociados" => array:1 [ 0 => array:19 [ "pii" => "S0001731021003720" "issn" => "00017310" "doi" => "10.1016/j.ad.2020.04.021" "estado" => "S300" "fechaPublicacion" => "2022-03-01" "aid" => "2785" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2022;113:310-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Foro de Residentes</span>" "titulo" => "FR-Criterios de clasificación 2019 del lupus eritematoso sistémico" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "310" "paginaFinal" => "312" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "RF-2019 Classification Criteria for Systemic Lupus Erythematosus" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "L. Serra-García, P.J. Barba, D. Morgado-Carrasco" "autores" => array:3 [ 0 => array:2 [ "nombre" => "L." "apellidos" => "Serra-García" ] 1 => array:2 [ "nombre" => "P.J." "apellidos" => "Barba" ] 2 => array:2 [ "nombre" => "D." "apellidos" => "Morgado-Carrasco" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021003720?idApp=UINPBA000044" "url" => "/00017310/0000011300000003/v2_202212210529/S0001731021003720/v2_202212210529/es/main.assets" ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Resident's Forum</span>" "titulo" => " RF-2019 Classification Criteria for Systemic Lupus Erythematosus" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "T310" "paginaFinal" => "T312" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "L. Serra-García, P.J. Barba, D. Morgado-Carrasco" "autores" => array:3 [ 0 => array:2 [ "nombre" => "L." "apellidos" => "Serra-García" ] 1 => array:2 [ "nombre" => "P.J." "apellidos" => "Barba" ] 2 => array:4 [ "nombre" => "D." "apellidos" => "Morgado-Carrasco" "email" => array:1 [ 0 => "danielmorgado@yahoo.com.ar" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Departamento de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "FR-Criterios de clasificación 2019 del lupus eritematoso sistémico" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with a broad spectrum of clinical and immunological manifestations, that is difficult to diagnose. The classification criteria for SLE are essential for standardization of cohorts and reproducibility of clinical trials.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">In 2019, the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) drew up new classification criteria for SLE<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a> (EULAR/ACR-2019). These were more sensitive and specific than the 1997 criteria of the ACR (ACR-1997) and the 2012 criteria of the Systemic Lupus International Collaborating Clinics (SLICC-2012). The methodology included an initial phase comprising a systematic review of the literature,<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a> a Delphi exercise with 145 international experts,<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a> a cohort of 616 patients with recent-onset SLE, and a survey of 339 individuals with SLE. In the second phase, 19 experts used the nominal group technique to reduce the number of classification criteria to 21.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a> In the third phase, the criteria were separated into clinical and immunological criteria. Weighting was based on a representative sample of patients with SLE, and pairs of criteria were compared using a multicriteria decision analysis. The last phase, of refinement and validation of the criteria, was based on a validation cohort comprising 1270 individuals (696 patients with SLE and 574 controls with diseases mimicking SLE). The sensitivity and specificity of the new criteria were 96.1% and 93.4%, respectively, which represents an improvement on the ACR-1997 and SLICC-2012 criteria,<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a> thus enabling greater accuracy and a lower percentage of false positives and negatives.</p><p id="par0015" class="elsevierStylePara elsevierViewall">The most relevant modification introduced by EULAR/ACR-2019 is the presence of antinuclear antibodies (ANA) at titers of ≥1/80 (measured as HEp-2 cells or equivalent) as an essential criterion, thus excluding patients with persistently negative ANA titers. This criterion is based on the results of a systematic review of 13 080 patients with SLE, in which an ANA titer ≥1/80 had 97.8% sensitivity.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">In addition, the clinical and immunological criteria were redesigned and are now subdivided into 7 clinical domains (constitutional, hematologic, neuropsychiatric, serosal, mucocutaneous, musculoskeletal, and renal) and 3 immunological domains (antiphospholipid antibodies, low complement levels, and SLE-specific antibody). Unexplained fever was included as a constitutional clinical criterion. Within each domain, the criteria are weighted with values ranging from 2 to 10 according to their relative weight in the diagnosis of SLE based on available scientific evidence. Therefore, based on the new criteria, diagnosis of SLE requires a positive ANA titer ≥1/80, a clinical criterion, and a score ≥10. The changes in weighting make it possible to classify as having SLE patients with class 3–4 lupus nephritis as the only clinical manifestation and a positive ANA titer. As for mucocutaneous criteria, even if a patient presents with various cutaneous manifestations that are typical of SLE, only that with the highest value will be scored (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). Therefore, in line with the new classification, it is not possible to classify an SLE patient based only on mucocutaneous findings.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">The new EULAR/ACR-2019 classification criteria for SLE are more sensitive and specific and include major modifications: positive ANA titers as an essential requirement, new clinical criteria, and changes in weighting. These are aimed at standardizing SLE cohorts and including individuals with a shorter disease course.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1590141" "palabras" => array:5 [ 0 => "Systemic lupus erythematosus" 1 => "Classification" 2 => "Antinuclear antibodies" 3 => "Cutaneous lupus erythematosus" 4 => "2019 EULAR/ACR" ] ] ] ] "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Abbreviations: ANA, antinuclear antibody; anti-dsDNA, anti-double stranded DNA antibody; anti-β2GP1, anti-ß2 glycoprotein 1; EULAR/ACR-2019, 2019 classification of the European League Against Rheumatism and the American College of Rheumatology for SLE; SLE, systemic lupus erythematosus.</p>" "tablatextoimagen" => array:2 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleBold">EULAR/ACR-2019</span>Entry criterion: ANA at titers<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>1/80Additive criteria: at least 1 clinical criterion and ≥<span class="elsevierStyleHsp" style=""></span>10 points<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a></th></tr><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Clinical domains \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Weight \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Constitutional \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Unexplained fever<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>38.5<span class="elsevierStyleHsp" style=""></span>°C<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hematologic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">LeukopeniaThrombocytopeniaAutoimmune hemolysis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">344 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Neuropsychiatric \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DeliriumPsychosisSeizure \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">235 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mucocutaneous \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Nonscarring alopeciaOral ulcersSubacute cutaneous or discoid lupus<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a>Acute cutaneous lupus<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2246 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Serosal \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pleural or pericardial effusionAcute pericarditis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">56 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Musculoskeletal \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Joint involvement \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Renal \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Proteinuria<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>0.5<span class="elsevierStyleHsp" style=""></span>μg/dRenal biopsy class 2 or 5 lupus nephritisRenal biopsy class 3 or 4 lupus nephritis<span class="elsevierStyleSup">d</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4810 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] 1 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Immunological domains</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Weight \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Antiphospholipid antibodies \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Anticardiolipin antibodies or anti-β2GP1 antibodies or lupus anticoagulant \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Complement proteins \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Low C3 or C4Low C3 and C4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">34 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SLE-specific antibodies \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Anti-dsDNA antibody or anti-Smith antibody \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] "notaPie" => array:3 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">The criteria are cumulative and do not need to be present simultaneously. Within each domain, only the highest-scoring criterion is counted for the total score.</p>" ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Unexplained fever<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>38.3<span class="elsevierStyleHsp" style=""></span>°C is a new clinical criterion in this classification.</p>" ] 2 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "c" "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Definitions:</p> <p class="elsevierStyleNotepara" id="npar0020">a. Subacute cutaneous lupus: annular or papulosquamous (psoriasiform) cutaneous eruption, usually photodistributed.</p> <p class="elsevierStyleNotepara" id="npar0025">- Skin biopsy: interface vacuolar dermatitis, perivascular lymphohistiocytic infiltrate, and/or dermal mucin.</p> <p class="elsevierStyleNotepara" id="npar0030">b. Discoid lupus erythematosus:</p> <p class="elsevierStyleNotepara" id="npar0035">- Erythematous-violaceous cutaneous lesions with atrophic scarring, dyspigmentation, follicular hyperkeratosis/plugging leading to scarring alopecia on the scalp.</p> <p class="elsevierStyleNotepara" id="npar0040">- Skin biopsy: interface vacuolar dermatitis, perivascular and/or periappendageal lymphohistiocytic infiltrate. Plugs may be observed on the scalp, as may be mucin deposition in longstanding lesions.</p> <p class="elsevierStyleNotepara" id="npar0045">c. Acute cutaneous lupus:</p> <p class="elsevierStyleNotepara" id="npar0050">- Malar rash or generalized maculopapular rash.</p> <p class="elsevierStyleNotepara" id="npar0055">- Skin biopsy: interface vacuolar dermatitis, perivascular lymphohistiocytic infiltrate, often with dermal mucin. Perivascular neutrophilic infiltrate may be present early in the course.</p> <p class="elsevierStyleNotepara" id="npar0060"><span class="elsevierStyleSup">d</span>Class 3 or 4 lupus nephritis itself indicates a total score of 10. ANA<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>1/80 is sufficient to classify a patient as having SLE.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Criteria for Systemic Lupus Erythematosus According to the New 2019 Classification of the European League Against Rheumatism and the American College of Rheumatology (EULAR/ACR-2019).</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0030" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Distinctions between diagnostic and classification criteria?" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Aggarwal" 1 => "S. Ringold" 2 => "D. Khanna" 3 => "T. Neogi" 4 => "S.R. Johnson" 5 => "A. Miller" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Arthritis Care Res" "fecha" => "2015" "volumen" => "67" "paginaInicial" => "891" "paginaFinal" => "897" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0035" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Aringer" 1 => "K. Costenbader" 2 => "D. Daikh" 3 => "R. Brinks" 4 => "M. Mosca" 5 => "R. Ramsey-Goldman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Arthritis Rheumatol Hoboken NJ" "fecha" => "2019" "volumen" => "71" "paginaInicial" => "1400" "paginaFinal" => "1412" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0040" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Performance of antinuclear antibodies for classifying systemic lupus erythematosus: a systematic literature review and meta-regression of diagnostic data" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Leuchten" 1 => "A. Hoyer" 2 => "R. Brinks" 3 => "M. Schoels" 4 => "M. Schneider" 5 => "J. Smolen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arthritis Care Res" "fecha" => "2018" "volumen" => "70" "paginaInicial" => "428" "paginaFinal" => "438" "itemHostRev" => array:3 [ "pii" => "S1542356520316396" "estado" => "S300" "issn" => "15423565" ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0045" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Multi-center delphi exercise reveals important key items for classifying systemic lupus erythematosus" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "G. Schmajuk" 1 => "B.F. Hoyer" 2 => "M. Aringer" 3 => "S.R. Johnson" 4 => "D.I. Daikh" 5 => "T. Dörner" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Arthritis Care Res" "fecha" => "2018" "volumen" => "70" "paginaInicial" => "1488" "paginaFinal" => "1494" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0050" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Methods of formal consensus in classification/diagnostic criteria and guideline development" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "R. Nair" 1 => "R. Aggarwal" 2 => "D. Khanna" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.semarthrit.2010.12.001" "Revista" => array:6 [ "tituloSerie" => "Semin Arthritis Rheum" "fecha" => "2011" "volumen" => "41" "paginaInicial" => "95" "paginaFinal" => "105" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21420149" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/00017310/0000011300000003/v2_202212210529/S0001731022001387/v2_202212210529/en/main.assets" "Apartado" => array:4 [ "identificador" => "93537" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Foro de Residentes / Resident's Forum" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/00017310/0000011300000003/v2_202212210529/S0001731022001387/v2_202212210529/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731022001387?idApp=UINPBA000044" ]
| año/Mes | Html | Total | |
|---|---|---|---|
| 2024 Noviembre | 35 | 19 | 54 |
| 2024 Octubre | 280 | 94 | 374 |
| 2024 Septiembre | 397 | 79 | 476 |
| 2024 Agosto | 272 | 126 | 398 |
| 2024 Julio | 218 | 71 | 289 |
| 2024 Junio | 188 | 115 | 303 |
| 2024 Mayo | 213 | 80 | 293 |
| 2024 Abril | 155 | 78 | 233 |
| 2024 Marzo | 196 | 87 | 283 |
| 2024 Febrero | 140 | 87 | 227 |
| 2024 Enero | 135 | 96 | 231 |
| 2023 Diciembre | 99 | 48 | 147 |
| 2023 Noviembre | 124 | 100 | 224 |
| 2023 Octubre | 152 | 99 | 251 |
| 2023 Septiembre | 117 | 83 | 200 |
| 2023 Agosto | 113 | 44 | 157 |
| 2023 Julio | 110 | 81 | 191 |
| 2023 Junio | 103 | 39 | 142 |
| 2023 Mayo | 94 | 36 | 130 |
| 2023 Abril | 73 | 28 | 101 |
| 2023 Marzo | 90 | 38 | 128 |
| 2023 Febrero | 57 | 33 | 90 |
| 2023 Enero | 80 | 45 | 125 |
| 2022 Diciembre | 89 | 56 | 145 |
| 2022 Noviembre | 108 | 74 | 182 |
| 2022 Octubre | 130 | 51 | 181 |
| 2022 Septiembre | 131 | 66 | 197 |
| 2022 Agosto | 129 | 68 | 197 |
| 2022 Julio | 145 | 51 | 196 |
| 2022 Junio | 142 | 64 | 206 |
| 2022 Mayo | 192 | 68 | 260 |
| 2022 Abril | 78 | 55 | 133 |
| 2022 Marzo | 99 | 64 | 163 |
| 2022 Febrero | 82 | 133 | 215 |
Mostrar todo
